Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department - PubMed
6 hours ago
- #Clinical Trial
- #Hyperkalaemia
- #Emergency Medicine
- Patiromer was studied as an adjunct treatment for hyperkalaemia (HK) in emergency departments (EDs).
- The PLATINUM trial was a randomised, double-blind, placebo-controlled study across 16 ED sites in the USA.
- Participants were adults with serum potassium ≥5.8 mEq/L, receiving standard therapy plus either patiromer or placebo.
- Primary outcome was net clinical benefit (NCB) at 6 hours, with no significant difference found between patiromer and placebo.
- Potassium levels and number of interventions were similar in both groups at all measured time points.
- Adverse events were not significantly different between the patiromer and placebo groups.
- The study was terminated early and was underpowered to detect statistical efficacy of patiromer over placebo.